# Month 30 & 42 Extension Studies of CRD-004 Primary Study

> **NCT00492648** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 34 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **PROCEDURE:** Blood sampling for assay of persistence of immunogenicity

## Key facts

- **NCT ID:** NCT00492648
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06-25
- **Primary completion:** 2008-06-23
- **Final completion:** 2008-06-23
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492648, "Month 30 & 42 Extension Studies of CRD-004 Primary Study". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00492648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*